

PPAR- γ agonists have potential therapeutic role in gastric carcinoma?

August 26 2009

Recently, the potential of PPAR- γ as a target for the prevention and treatment of cancer has been widely studied. However, the potential therapeutic role of PPAR- γ agonists has been questioned, based on contradictory results. Studies using animal models of colon cancer found that PPAR- γ agonists increased the development of colon tumors.

This contradictory result was supplemented by a recent report using transgenic mice expressing a constitutive active form of PPAR- γ in [mammary glands](#) which showed that PPAR- γ signaling accelerated tumor development in mammary glands. The actual role of PPAR- γ in cancer has been complicated by recent findings that PPAR- γ agonists affect cancer cells independently of PPAR- γ , and silencing of PPAR- γ and a PPAR- γ antagonist inhibit cancer cell growth. To date, the role of PPAR- γ in gastric carcinogenesis remains unclear.

A research article to be published on August 21, 2009 in the [World Journal of Gastroenterology](#) addresses this question. A study from China found that PPAR- γ may be involved in gastric carcinogenesis, and that the PPAR- γ agonist 15d-PGJ2 may inhibit the growth of human gastric carcinoma MGC803 cell by inducing apoptosis and G1/G0 arrest, involving survivin, Skp2 and p27, but via a PPAR- γ -independent pathway.

The study showed that the PPAR- γ agonist 15d-PGJ2 inhibited growth of cultured gastric [cancer](#) MGC803 cells, and demonstrated that the PPAR- γ antagonist GW9662 did not block this effect of 15d-PGJ2 and

that 2.5 μ M GW9662 inhibited growth of MGC803 cells. Furthermore, PPAR- γ siRNA remarkably inhibited the growth of MGC803 cells.

These results indicated that 15d-PGJ2 inhibited growth of cultured gastric carcinoma MGC803 cells by a PPAR- γ -independent pathway. These results also suggest that PPAR- γ agonists could be useful in the chemoprevention or chemotherapy of gastric malignancies.

More information: Ma XM, Yu H, Huai N. Peroxisome proliferator-activated receptor-g is essential in the pathogenesis of gastric carcinoma. *World J Gastroenterol* 2009; 15(31): 3874-3883;
www.wjgnet.com/1007-9327/15/3874.asp

Source: World Journal of Gastroenterology ([news](#) : [web](#))

Citation: PPAR-g agonists have potential therapeutic role in gastric carcinoma? (2009, August 26) retrieved 19 April 2024 from <https://medicalxpress.com/news/2009-08-ppar-g-agonists-potential-therapeutic-role.html>

<p>This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.</p>
--